In renal carcinoma cell lines, treatment with a PI3K or AKT inhibitor reduces FSCN1 protein and mRNA expression, indicating that FSCN1 may be regulated through the PI3K/AKT axis (Figure 2) 72. Here, FSCN1 is linked to renal carcinoma.